Nanologica AB Extends Existing Loan from Flerie Invest AB
24 March, 2025
No Comments
Nanologica has extended the existing loan from Flerie Invest AB. The end date for the loan has been extended to
Investor relations (EN)
This is Nanologica
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. With a foundation in materials science and nanotechnology, we have developed an expertise in chromatography. Our products are used to purify pharmaceuticals during production using a technique called preparative chromatography.
We operate in a global niche market that is growing as a result of an increased demand for drugs for treating diabetes and obesity. Our silica-based purification media for preparative chromatography, NLAB Saga®, has been especially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for NLAB Saga®, it can increase productivity and reduce costs for pharmaceutical manufacturers.
Our mission is to increase access to cost-effective drugs through its purification products, and thereby enable more patients around the world access to life-saving treatments for diabetes and obesity.
Read more:
5 Reasons
to invest in Nanologica
By developing chromatography products that enable pharmaceutical manufacturers to streamline production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access to adequate treatments.
Year-End Report 2024 Nanologica AB (publ)
14 February, 2025
No Comments
FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to SEK 6,715 thousand (75) and for the full year
Change of Dates for Year-End Report 2024 for Nanologica AB
4 February, 2025
No Comments
Due to technical reasons, Nanologica AB moves the year-end report for 2024 to Friday, February 14. The year-end report will
Bokslutskommuniké 2024 Nanologica AB (publ)
14 February, 2025
No Comments
FINANSIELL SAMMANFATTNING • Nettoomsättningen för fjärde kvartalet uppgick till 6 715 TSEK (75) och för helåret till 14 538 TSEK
Year-End Report 2024 Nanologica AB (publ)
14 February, 2025
No Comments
FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to SEK 6,715 thousand (75) and for the full year
Interim Report Q3 2024 Nanologica AB (publ)
8 November, 2024
No Comments
FINANCIAL SUMMARY • Net sales for the third quarter amounted to SEK 611 thousand (342) and for the nine-month period
Annual Report 2023
2023 has been marked by geopolitical tensions and macroeconomic uncertainty. Like most others, Nanologica has been affected by this and we have had to prioritize our resources. On the other hand, we operate in a market segment that is virtually insensitive to economic cycles. We expect a commercial breakthrough in the near future and have a clear growth strategy for how we can capitalize on the strong market growth that exists in drugs for the treatment of diabetes and obesity.
Presentation of Nanologica
Follow this link for more video presentations and CEO interviews.
Company presentation made by CEO Andreas Bhagwani in June, 2023.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
Subscribe to our news
For further information, please contact:
Johanna Johansson
Director IR, Communications and Marketing
